Author:
Jiang Xiu-Yun,Chen Qing,Chen Xiao-Yu,Sun Qiu-Ying,Jing Fei,Zhang Hai-Qing,Xu Jin,Li Xiao-Hong,Guan Qing-Bo
Abstract
Abstract
Aim
To examine the prognostic value of superoxide dismutase (SOD) activity for monitoring reduced left ventricular ejection fraction(LVEF)in the patients with type 2 diabetes and acute coronary syndrome (ACS).
Methods
The population of this cross-sectional study included 2377 inpatients with type 2 diabetes who had an ACS admitted to the Shandong Provincial Hospital Affiliated to Shandong First Medical University from January 2016 to January 2021.
Results
Diabetic patients with ACS were divided into 2 subgroups based on LVEF. The mean SOD activity was significantly lower in patients with an LVEF ≤ 45% than in those with an LVEF > 45% (149.1 (146.4, 151.9) versus 161.9 (160.8, 163.0)). Using ROC statistic, a cut-off value of 148.8 U/ml indicated an LVEF ≤ 45% with a sensitivity of 51.6% and a specificity of 73.7%. SODs activity were found to be correlated with the levels of NT-proBNP, hs-cTnT, the inflammatory marker CRP and fibrinogen. Despite taking the lowest quartile as a reference (OR 0.368, 95% CI 0.493–0.825, P = 0.001) or examining 1 normalized unit increase (OR 0.651, 95% CI 0.482–0.880, P = 0.005), SOD activity was found to be a stronger predictor of reduced LVEF than CRP and fibrinogen, independent of confounding factors.
Conclusions
Our cross-sectional study suggests that SOD activity might be a valuable and easily accessible tool for assessing and monitoring reduced LVEF in the diabetic patients with ACS.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Xiu-Yun Jiang QC, Chen X-Y, Sun Q-Y. Fei Jing, and 4 more. Association between Superoxide Dismutase, C-Reactive Protein, Fibrinogen and Heart Failure in Patients with Diabetes and Acute Coronary Syndrome. https://www.researchsquare.com/article/rs-1733313/v1.
2. Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, Zethelius B, et al. Risk factors, mortality, and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44. Epub 2018/08/16.
3. Karakayali M, Omar T, Artac I, Ilis D, Arslan A, Altunova M, et al. The prognostic value of HALP score in predicting in-hospital mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2023;34(7):483–8. Epub 2023/10/06.
4. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–7. Epub 2000/10/25.
5. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. Epub 2006/10/13.